Supplementary Data S1 from &lt;i&gt;Ad hoc&lt;/i&gt; Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline &lt;i&gt;BRCA&lt;/i&gt; Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects